Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on April 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on April 16, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions at weighted average prices of $9.2804 and $9.2797, with prices ranging from $9.05 to $9.47.
• Following the transactions, Tanimoto directly owns 3,276,854 shares.
• Tanimoto also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and holdings by her spouse.
• She disclaims beneficial ownership of shares held by the Richard E. Lowenthal Charitable Remainder UniTrust, where her spouse serves as trustee.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to insider trading under a pre-arranged plan, so it doesn't convey strong positive or negative sentiment.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals, though often noisy, about management's view of the company's prospects. In this case, the sales were pre-planned under a 10b5-1 plan, which mitigates concerns about trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates